Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis

CONCLUSIONS: Sintilimab could be considered the cost-effective second-line strategy for patients with advanced or metastatic squamous non-small-cell lung cancer compared with docetaxel in China.PMID:37789675 | DOI:10.1080/14737167.2023.2267177

Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 4, 2023 Category: Health Management Authors: Mochong Liao Shuo Kang Source Type: research